title: [Lithium and its effects on the endocrine system, bones and peripheral nerves--a current review].
abstract: Controlled studies in 1990-1992 with Danish, Sardinian, and Hongkong-Chinese patients consistently revealed a prevalence of goiter of about 50% in lithium treated patients. This is far beyond the frequency generally assumed for Germany, the whole country still known to be an endemic goiter area. Hypothyroidism as a side effect of lithium occurs in a clearly different group of patients and is much less frequent, the overall incidence being not substantially different from the incidence in the general population. But the risk of becoming hypothyroid as well as hyperparathyroid during lithium prophylaxis is markedly higher in women over 45 years of age, who in the general population are also prone to both endocrine dysfunctions. Lithium is considered to have a provoking role. Lithium is known to be accumulated in the bone and an impact on bone metabolism was shown in animal studies. The data reviewed prohibit the use of lithium during lactation and enforce strict indication in children. In adults the effect of lithium on bone should be considered only in osteomalacia and severe osteoporosis. This review is illustrated by the case of a 60-year-old woman, who after 4 years of successful treatment with lithiumcarbonate because of schizoaffective psychosis, developed a syndrome of hypercalcemia. Exstirpation of a parathyroid adenoma rendered her normocalcemic. Moreover, a pre-existing diffuse goiter had grown to a large nodular goiter within the course of her 5-year treatment. As she finally became paraparetic, she was admitted to our rehabilitation center for the diseases of the spinal cord. Her paraparesis may have been caused not only by the lithium-induced primary HPT, but in part by lithium itself. There are a few reports on lithium causing peripheral neuropathy at toxic levels. A transient deterioration of a pre-existing neuropathy, as in our case study, may have happened at lithium serum levels not far beyond the upper limit of 0.8 mmol/l.
authors.affiliation: Neurologische Klinik und Rehabilitationsklinik für Rückenmarkverletzte Hohe Warte, Bayreuth.
authors.forename: U
authors.initials: U
authors.lastname: Leutgeb
mesh_terms: D000328:Adult; D001842:Bone and Bones / Q000187:drug effects*; D002648:Child; D004305:Dose-Response Relationship, Drug; D005260:Female; D006044:Goiter, Nodular / Q000139:chemically induced; D006801:Humans; D006934:Hypercalcemia / Q000139:chemically induced; D006961:Hyperparathyroidism / Q000139:chemically induced; D016651:Lithium Carbonate / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D010280:Parathyroid Glands / Q000187:drug effects*; D010525:Peripheral Nerves / Q000187:drug effects*; D011618:Psychotic Disorders / Q000188:drug therapy; D013118:Spinal Cord Diseases / Q000139:chemically induced; D013961:Thyroid Gland / Q000187:drug effects*
chemical_list: D016651:Lithium Carbonate
vernacular_title: Lithium und seine Wirkungen auf das Endokrinium, den Knochen und den peripheren Nerv--eine aktuelle Ubersicht.